ES2285087T3 - Formas farmaceuticas de adn. - Google Patents

Formas farmaceuticas de adn. Download PDF

Info

Publication number
ES2285087T3
ES2285087T3 ES03700947T ES03700947T ES2285087T3 ES 2285087 T3 ES2285087 T3 ES 2285087T3 ES 03700947 T ES03700947 T ES 03700947T ES 03700947 T ES03700947 T ES 03700947T ES 2285087 T3 ES2285087 T3 ES 2285087T3
Authority
ES
Spain
Prior art keywords
dna
pharmaceutical
agent
pharmaceutical agent
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03700947T
Other languages
English (en)
Spanish (es)
Inventor
Ian Richard GlaxoSmithKline CATCHPOLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0201736.6A external-priority patent/GB0201736D0/en
Priority claimed from GB0201735A external-priority patent/GB0201735D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2285087T3 publication Critical patent/ES2285087T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES03700947T 2002-01-25 2003-01-23 Formas farmaceuticas de adn. Expired - Lifetime ES2285087T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
GB0201735A GB0201735D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
GB0201735 2002-01-25
GB0201736 2002-01-25

Publications (1)

Publication Number Publication Date
ES2285087T3 true ES2285087T3 (es) 2007-11-16

Family

ID=27614803

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03700947T Expired - Lifetime ES2285087T3 (es) 2002-01-25 2003-01-23 Formas farmaceuticas de adn.

Country Status (8)

Country Link
US (2) US20050085434A1 (https=)
EP (1) EP1467711B1 (https=)
JP (1) JP2005519905A (https=)
AT (1) ATE357219T1 (https=)
CA (1) CA2473717A1 (https=)
DE (1) DE60312645T2 (https=)
ES (1) ES2285087T3 (https=)
WO (1) WO2003061629A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538628A (en) * 2002-08-12 2008-06-30 Dynavax Tech Corp Immunomodulatory compositions, methods of making, and methods of use thereof
AU2002951692A0 (en) * 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
GB0423681D0 (en) * 2004-10-26 2004-11-24 Sec Dep For Environment Food & Vaccine and nucleic acids
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE235558T1 (de) * 1989-06-26 2003-04-15 Powderject Vaccines Inc Transformation von tierischen somatischen zellen mittels partikeln
DK28792D0 (da) * 1992-03-04 1992-03-04 Novo Nordisk As Nyt enzym
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
CA2158733C (en) * 1994-01-21 2007-01-16 Dennis E. Mccabe Gas driven gene delivery instrument
ES2208687T3 (es) * 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
EP0906110B1 (en) * 1996-04-26 2004-12-22 Merck & Co., Inc. Dna vaccine formulations

Also Published As

Publication number Publication date
US20050085434A1 (en) 2005-04-21
ATE357219T1 (de) 2007-04-15
WO2003061629A2 (en) 2003-07-31
WO2003061629A3 (en) 2003-10-02
JP2005519905A (ja) 2005-07-07
DE60312645T2 (de) 2007-11-29
EP1467711B1 (en) 2007-03-21
US20080095854A1 (en) 2008-04-24
DE60312645D1 (de) 2007-05-03
CA2473717A1 (en) 2003-07-31
EP1467711A2 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
ES2295768T3 (es) Agujas recubiertas con vacuna.
ES2322572T3 (es) Formas de dosificacicon de adn.
ES2372592T3 (es) Formulación seca para la inmunización transcutánea.
US8377654B2 (en) Stable galenic freeze-dried pharmaceutical preparation of recombinant carbohydrate-binding polypeptides
US20080095854A1 (en) Dna dosage forms
CA2424160A1 (en) Oral solid dose vaccine
EP1528914B1 (en) Antigenic compositions
JP2015512441A (ja) 経口ワクチン投与のための改善アジュバント系
US20050002969A1 (en) Binary composition for prime-boost release of active ingredients like vaccines
ES2360698T3 (es) Vacunas mejoradas contra el antrax y procedimientos de administración.
WO2005102394A1 (en) Uric acid as adjuvant